探讨瑞替普酶与阿替普酶在急性ST段抬高型心肌梗死溶栓治疗中的应用效果  

Study of reteplase and alteplase in acute ST elevation myocardial infarction treatment effect

作　　者：朱晓庆 张金瑞[1] 齐春霞[1] Zhu Xiaoqing;Zhang Jinrui;Qi Chunxia(Department of Cardiology,General Hospital of Jinlin Oil Field,Songyuan,Jilin,138000,China)

机构地区：[1]吉林油田总医院心内二科,吉林松原138000

出　　处：《当代医学》2018年第18期86-88,共3页Contemporary Medicine

摘　　要：目的观察并探讨瑞替普酶与阿替普酶在急性ST段抬高型心肌梗死溶栓治疗中的应用效果及临床使用价值。方法在本院2015年4月~2017年5月间收治的急性ST段抬高型心肌梗死患者中选择68例进行此次分组治疗,将68例患者依据数字表法分为A组及B组,A组34例患者均使用瑞替普酶进行溶栓治疗,B组34例患者则使用阿替普酶进行溶栓治疗。结果 A组患者血管再通率为79.4%,B组为76.5%,A组与B组比较差异无统计学意义。A组并发症发生率为2.9%明显低于B组17.6%,A组与B组比较差异具有统计学意义(P<0.05)。结论瑞替普酶与阿替普酶在急性ST段抬高型心肌梗死溶栓治疗中均具有良好的治疗效果,但瑞替普酶的并发症发生率更低,安全性更高,值得推广。Objective Observe and evaluate the effect of reteplase and alteplase application effect in acute ST elevation myocardial infarction treatment and clinical value. Methods In acute ST patients in our hospital in April 2015-May 2017 year from elevation myocardial infarction in 68 cases of the treatment group, 68 cases on the basis of randomly divided into A group and B group, A group of 34 patients using reteplase thrombolytic therapy, B group of 34 patients using atenolol enzyme thrombolytic therapy. Results The recanalization rate was 79.4% in group A and 76.5% in group B, and there was no significant difference between group A and group B. The incidence of complications in group A was 2.9%, which was significantly lower than that in group B（17.6%）, and there was significant difference between group A and group B（P〈0.05）. Conclusion Reteplase and alteplase has good therapeutic effect in patients with acute ST elevation myocardial infarction treatment, but the incidence of complications of reteplase is lower, higher security, worthy of promotion.

关 键 词：瑞替普酶 阿替普酶 急性ST段抬高型心肌梗死 溶栓治疗 

分 类 号：R542.22[医药卫生—心血管疾病]